FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

July 14, 2021
1:56 pm

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

KRAKOW, Poland, July 14, 2021 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the U.S. Food…

Click here to view the original article.

Global, PRNewswire

Share this article

Crypto market embraces AI and structural growth in 2026

February 25, 2026

JPM: HSBC HOLDINGS Results & Guidance Beat; Stock Price Likely to React Positively AASTOCKS Financial News

February 25, 2026

U.S. Senator opens probe on Binance over alleged $1.7 billion flow to Iranian entities

February 25, 2026

IT Spending Will Exceed $6 Trillion for the First Time in 2026 Thanks to Artificial Intelligence (AI). Here’s How to Invest.

February 25, 2026

FIG rises in premarket after big insider buy, ARK adds shares

February 25, 2026

Bitcoin, Ethereum, XRP test rebound strength as ETF inflows return

February 25, 2026

Assessing Spotify Technology (SPOT) After Recent Share Price Pullback

February 25, 2026

Nuclear Energy Isn’t Scary Anymore. It’s Just Crypto-Coded

February 25, 2026